Source: Eur Respir Monogr 2015; 69: 197-212
Disease area: Airway diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
David J. Serisier. Prophylactic antibiotics. Eur Respir Monogr 2015; 69: 197-212

Member's Comments

No comment yet.

Related content which might interest you: Long-term antibiotic therapy Source: International Congress 2017 – PG3 Bronchiectasis Year: 2017 Colistin as a first choice antibiotic for the initial empiric antimicrobial therapy of ventilator-associated pneumonia Source: Eur Respir J 2007; 30: 1234-1235 Year: 2007 Survival benefit of beta-lactam plus macrolide combined therapy versus beta-lactam plus quinolones in hospitalized community-acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies Year: 2016 Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia Source: Eur Respir Rev 2007; 16: 33-39 Year: 2007 Efficacy and safety of chemotherapy regimens containing fluoroquinolones in pediatric TB Source: Virtual Congress 2021 – Epidemiology and burden of tuberculosis and other lung diseases Year: 2021 Comparison of conventional and sequential antibiotic therapy of community-acquired pneumonia with levofloxacin and moxifloxacin Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 Practical treatment of community acquired pneumonia (CAP) with outpatient parenteral antibiotic therapy (OPAT) and switch therapy: CTRX and LVFX Source: Annual Congress 2008 - Diagnostic tests in lower respiratory tract infections Year: 2008 Inhaled antibiotic therapy Source: Annual Congress 2013 –PG9 How to optimise antibiotic use in respiratory infections Year: 2013 Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP Source: Eur Respir J 2013; 41: 123-130 Year: 2013 Effectiveness and safety of gatifloxacin in patients with drug resistance tuberculosus befor unsuccessfully treated with ofloxacin and ciprofloxacin Source: Eur Respir J 2006; 28: Suppl. 50, 588s Year: 2006 Active monitoring of adverse drug reactions to the use of beta-lactam antibiotics in the treatment of community-acquired pneumonia Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections Year: 2020 Oral vs. inhaled antibiotic therapy Source: International Congress 2015 – Bronchiectasis in Europe: an update from the European Bronchiectasis Network (EMBARC) Year: 2015 Inhaled antibiotics in ventilator-associated pneumonia: treatment or prophylaxis? Source: International Congress 2016 – PG13 Inhaled antibiotics in respiratory infections Year: 2016 Evaluation of antituberculous drugs administration Source: Eur Respir J 2002; 20: Suppl. 38, 547s Year: 2002 Combination therapy with intrapleural doxycycline and talc in reduced doses for pleurodesis Source: Annual Congress 2012 - Clinical issues in malignant pleural effusions Year: 2012 Beta lactam plus macrolide antibiotic combination therapy reduces the mortality of community-acquired pneumococcal pneumonia more than beta lactam antibiotics alone Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014